Patents by Inventor Phillip Hayes
Phillip Hayes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170236621Abstract: A cable comprising hybrid carbon nanotube (CNT) shielding includes at least one conducting wire; at least one insulating layer covering at least one of the at least one conducting wire; a metallic foil component configured for lower frequency shielding function; and a CNT tape component configured for higher frequency shielding function.Type: ApplicationFiled: May 2, 2017Publication date: August 17, 2017Inventors: Edward M. Silverman, James Grant, Thomas Kukowski, Michael Matuszewski, Kevin Voigt, Thomas Swanson, Phillip Hayes
-
Patent number: 9685258Abstract: A cable comprising hybrid carbon nanotube (CNT) shielding includes at least one conducting wire; at least one insulating layer covering at least one of the at least one conducting wire; a metallic foil component configured for lower frequency shielding function; and a CNT tape component configured for higher frequency shielding function.Type: GrantFiled: November 9, 2012Date of Patent: June 20, 2017Assignees: Northrop Grumman Systems Corporation, Minnesota Wine & CableInventors: Edward M. Silverman, James Grant, Thomas Kukowski, Michael Matuszewski, Kevin Voigt, Thomas Swanson, Phillip Hayes
-
Patent number: 9101561Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2ORF2 protein, and immunogenic compositions comprising PCV2ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2ORF2 protein, or an immunogenic composition comprising PCV2ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.Type: GrantFiled: January 9, 2012Date of Patent: August 11, 2015Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Patent number: 9011868Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: May 12, 2011Date of Patent: April 21, 2015Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20140131096Abstract: A cable comprising hybrid carbon nanotube (CNT) shielding includes at least one conducting wire; at least one insulating layer covering at least one of the at least one conducting wire; a metallic foil component configured for lower frequency shielding function; and a CNT tape component configured for higher frequency shielding function.Type: ApplicationFiled: November 9, 2012Publication date: May 15, 2014Applicants: MINNESOTA WIRE & CABLE, NORTHROP GRUMMAN SYSTEMS CORPORATIONInventors: Edward M. Silverman, James Grant, Thomas Kukowski, Michael Matuszewski, Kevin Voigt, Thomas Swanson, Phillip Hayes
-
Publication number: 20120107348Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: January 9, 2012Publication date: May 3, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Patent number: 8119143Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.Type: GrantFiled: June 11, 2008Date of Patent: February 21, 2012Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Publication number: 20110217327Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: May 12, 2011Publication date: September 8, 2011Applicant: Boehringer Ingelheim Vetmedica, IncInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7968285Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: June 11, 2008Date of Patent: June 28, 2011Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7838214Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: June 11, 2008Date of Patent: November 23, 2010Assignee: Boehringer Ingelheim Vetmedical, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7838213Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: June 11, 2008Date of Patent: November 23, 2010Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7829273Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: June 11, 2008Date of Patent: November 9, 2010Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7610676Abstract: A method for assembling a bundle cable connector assembly that eliminates bird caging, wire threads extruding through a connector pin, loose wire threads, dielectric shield shrinking, etc. The method includes stripping the wire to create a birdcage preventative zone and an exposed tip with a crimping zone therebetween, and tinning the exposed wire at the birdcage preventative zone and the tip. The method then includes inserting the wire into a connector pin, and crimping the pin to the wire at the crimping zone using heat so that the tinning solder melts. The method then includes mounting the pin to a connector body and mounting a wire-locking device to the connector body to lock the pin to the connector body.Type: GrantFiled: February 19, 2007Date of Patent: November 3, 2009Assignee: Northrop Grumman Space & Missions Systems Corp.Inventors: Dean Tran, Alan Hirschberg, Melissa Fuller, Phillip Hayes, Greg Keller
-
Publication number: 20090092636Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: June 11, 2008Publication date: April 9, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Publication number: 20080279875Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: November 13, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080279876Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: November 13, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080279889Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: November 13, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080267995Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: October 30, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080260779Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: October 23, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080261887Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: October 23, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer